LDHA and melanoma: A novel anti-CSCs drug (35b), derived from the natural chemical scaffold of symplostatin 4 (a natural anti-malaria depsipeptide), was reported to exhibit a significant inhibitory effect on melanoma growth by reducing CSC traits, such as melanosphere formation and ALDH expression, by impairing the Wnt/β-catenin signaling pathway [168].